Search Results
Mar 16, 2026, 05:31 ET Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
For over two decades, Piramal Pharma Solutions has been a global leader in ADC development and manufacturing. As the first FDA-approved ADC CDMO and the first CDMO to commercially manufacture an ADC, Piramal demonstrates unmatched proficiency in this segment.Piramal leverages this expertise to provide
More news about: Piramal Pharma Solutions
Mar 16, 2026, 05:27 ET Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
For over two decades, Piramal Pharma Solutions has been a global leader in ADC development and manufacturing. As the first FDA-approved ADC CDMO and the first CDMO to commercially manufacture an ADC, Piramal demonstrates unmatched proficiency in this segment.Piramal leverages this expertise to provide
More news about: Piramal Pharma Solutions
Mar 13, 2026, 09:00 ET BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards
BioDlink, an innovation-driven Contract Development and Manufacturing Organization (CDMO), today announced that it has been named "Emerging CDMO of the Year" at the Asia-Pacific Biopharma Excellence Awards, organized by IMAPAC.
More news about: BioDlink Biopharm Co., Ltd.
Mar 11, 2026, 19:41 ET Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit
/PRNewswire/ -- Locus Cell Co., Ltd. ("Locus Cell"), a Taiwan-based cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO), and Charles River Laboratories ("Charles River"), a global contract research organization (CRO) providing drug development support and biologics testing
More news about: Locus Cell Co., Ltd.
Mar 10, 2026, 08:30 ET mAbxience Selects Genedata Bioprocess to Automate End-to-End CDMO Workflows
source of truth for all CDMO operations. This strategic move positions mAbxience to increase operational efficiency and advance toward AI-driven process optimization."We are delighted to welcome mAbxience to the Genedata community, and to further expand our footprint in the CDMO industry," said Othmar
More news about: Genedata
Mar 10, 2026, 08:30 ET Biomanufacturing Strategies for Accelerated Modular Scale-Up and Supply, Upcoming Webinar Hosted by Xtalks
Attendees will gain insight into the role of single-use technologies and standardized layouts in rapid scale-up. The speakers will share how experienced CDMO partners translate flexibility into reliable execution.TORONTO, March
More news about: Xtalks
Mar 10, 2026, 08:00 ET Andelyn Biosciences Establishes The Andelyn Foundation to Support Families Living with Rare and Ultra-Rare Diseases
2026 /PRNewswire/ -- Andelyn Biosciences Inc., a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the unveiling of
More news about: Andelyn Biosciences
Mar 10, 2026, 07:00 ET Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea
March 10, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced a collaboration agreement with Eli Lilly and Company (Lilly) to establish a Lilly Gateway Labs (LGL) site in Korea.
More news about: Samsung Biologics
Mar 10, 2026, 07:00 ET Novella names Antonio Martinez Descalzo as CEO to Lead Expansion
Biosynthesis, Srl, the industrial division of Insud Pharma Group, S.L.. Chemo specializes in providing contract development and manufacturing organization (CDMO) services for the pharmaceutical sector.In a strategic contract-manufacturing partnership, Chemo is integrating Novella's proprietary technology
More news about: Novella
Mar 08, 2026, 22:25 ET LOTTE Biologics to Participate in DCAT Week 2026 in New York to Explore Global Partnership Opportunities
March 23 to 26, to explore new partnership opportunities and strengthen its global presence in the contract development and manufacturing organization (CDMO) sector.
More news about: Lotte Biologics
Mar 05, 2026, 10:16 ET Lipid Nanoparticles Market to Reach $3.1 Billion, Globally, by 2033 at 13.1% CAGR: Allied Market Research
acquisition of Exelead for approximately $780 million in cash, following regulatory approvals and customary closing conditions. Exelead, a biopharmaceutical CDMO, specializes in PEGylated products and complex injectable formulations, including LNP-based drug delivery technologies, which are essential for mRNA
More news about: Allied Market Research
Mar 05, 2026, 09:37 ET Kenox Pharmaceuticals Inc. Announces Clinical Manufacturing Readiness for Nasal and Inhaled Drug Products
March 4, 2026 /PRNewswire/ -- Kenox Pharmaceuticals Inc. (Kenox), a fast‑growing contract development and manufacturing organization (CDMO) dedicated exclusively to Orally Inhaled and Nasal Drug Products (OINDPs) and Ophthalmic Drug Products, today announced that it is now fully Clinical
More news about: Kenox Pharmaceuticals Inc.
Mar 04, 2026, 10:27 ET Frontage Laboratories Completes Acquisition of Teddy Lab, Strengthening Global Central Laboratory Capabilities
EXTON, Pa., March 4, 2026 /PRNewswire/ -- Frontage Laboratories, Inc. ("Frontage"), a leading global CRO/CDMO, today announced the completion of the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd. ("Teddy Lab"), a leading clinical research
More news about: Frontage Laboratories, Inc.
Mar 04, 2026, 09:00 ET Altruist Biologics Launches Altru-CON™ High-Concentration Formulation Platform to Accelerate Biologics Development
2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), recently announced the launch of Altru-CON™, a high-concentration formulation technology platform, designed to accelerate the development and commercialization
More news about: Altruist Biologics
Mar 04, 2026, 09:00 ET Altruist Biologics Launches Altru-CON™ High-Concentration Formulation Platform to Accelerate Biologics Development
2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), recently announced the launch of Altru-CON™, a high-concentration formulation technology platform, designed to accelerate the development and commercialization
More news about: Altruist Biologics
Mar 04, 2026, 08:00 ET Minaris Launches AgentSCREEN Adventitious Virus Detection by NGS to Simplify Viral Safety Testing for Cell Banks and Cell-Based Samples
March 4, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced the launch of AgentSCREEN Adventitious Virus Detection by Next Generation Sequencing
More news about: Minaris Advanced Therapies
Mar 04, 2026, 04:00 ET Codis Unlocks Commercial-Scale Amorphous Solid Dispersions Manufacturing with GEA PSD4 Solvent Spray Dryer Investment
organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering, announced a major expansion of its UK manufacturing capabilities with the purchase of a GEA Pharma-SD® type PSD-4 solvent-capable spray dryer. Codis will become the only UK CDMO offering
More news about: Codis
Mar 04, 2026, 04:00 ET Codis Unlocks Commercial-Scale Amorphous Solid Dispersions Manufacturing with GEA PSD4 Solvent Spray Dryer Investment
organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering, announced a major expansion of its UK manufacturing capabilities with the purchase of a GEA Pharma-SD® type PSD-4 solvent-capable spray dryer. Codis will become the only UK CDMO offering
More news about: Codis
Mar 02, 2026, 09:20 ET Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
(NASDAQ: SCNI) is a biopharmaceutical company operating a contract development and manufacturing organization (CDMO) alongside a focused immunology R&D pipeline.The Company's wholly owned CDMO unit provides fee-for-service development and manufacturing solutions to biotech and pharmaceutical companies
More news about: Scinai Immunotherapeutics Ltd.
Feb 26, 2026, 08:00 ET SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
IDT BiologikaWith passion we bring pharmaceutical solutions to life.IDT Biologika, part of SK bioscience, is a globally operating CDMO specializing in end-to-end development and manufacturing of biologics, biosimilars, and other sterile injectables. With more than 100 years of biopharmaceutical
More news about: SK bioscience
Feb 25, 2026, 11:01 ET C.A. Fortune Appoints Matt Ulmer as Chief Digital & Marketing Officer
full-service national sales brokerage and marketing agency, announced today the appointment of Matt Ulmer as Chief Digital & Marketing Officer (CDMO), unifying the company's marketing, digital, e–commerce, and corporate marketing capabilities under one executive leader. Ulmer will report to CEO Tyler
More news about: C.A. Fortune
Feb 25, 2026, 10:00 ET Biorep Technologies Marks 40th Anniversary of the Ricordi® Chamber, Reinforcing Its Leadership in Life Sciences Manufacturing Excellence
Biorep Technologies, a leading medical device contract design and manufacturing organization (CDMO) with more than 30 years of experience enabling scientific progress in diabetes, cell therapy, and regenerative medicine through advanced cell and tissue
More news about: Biorep Technologies, Inc.
Feb 25, 2026, 09:00 ET SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
pioneering biosimilar therapies.About Shilpa BiologicalsShilpa Biologicals is an integrated biopharmaceutical company with a hybrid CDMO model. It offers development, manufacturing, and ready-to-license formulations in immunology, oncology, and ophthalmics.Logo:
More news about: Shilpa Medicare Limited
Feb 25, 2026, 08:11 ET Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
small-molecule site in alignment with its CDMO expansion strategy.About Scinai ImmunotherapeuticsScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company operating a contract development and manufacturing organization (CDMO) alongside a focused immunology R&D
More news about: Scinai Immunotherapeutics Ltd.
Feb 25, 2026, 04:00 ET SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
pioneering biosimilar therapies.About Shilpa BiologicalsShilpa Biologicals is an integrated biopharmaceutical company with a hybrid CDMO model. It offers development, manufacturing, and ready-to-license formulations in immunology, oncology, and ophthalmics.Logo:
More news about: Shilpa Medicare Limited